163 related articles for article (PubMed ID: 37839346)
1. Development of potent isoflavone-based formyl peptide receptor 1 (FPR1) antagonists and their effects in gastric cancer cell models.
Francavilla F; Sarcina F; Schepetkin IA; Kirpotina LN; Contino M; Schirizzi A; De Leonardis G; Khlebnikov AI; D'Alessandro R; Quinn MT; Lacivita E; Leopoldo M
Eur J Med Chem; 2023 Dec; 261():115854. PubMed ID: 37839346
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
3. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A
Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443
[TBL] [Abstract][Full Text] [Related]
4. Application of small molecule FPR1 antagonists in the treatment of cancers.
Ahmet DS; Basheer HA; Salem A; Lu D; Aghamohammadi A; Weyerhäuser P; Bordiga A; Almeniawi J; Rashid S; Cooper PA; Shnyder SD; Vinader V; Afarinkia K
Sci Rep; 2020 Oct; 10(1):17249. PubMed ID: 33057069
[TBL] [Abstract][Full Text] [Related]
5. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Ragone C; Minopoli M; Ingangi V; Botti G; Fratangelo F; Pessi A; Stoppelli MP; Ascierto PA; Ciliberto G; Motti ML; Carriero MV
J Exp Clin Cancer Res; 2017 Dec; 36(1):180. PubMed ID: 29216889
[TBL] [Abstract][Full Text] [Related]
7. AZ2158 is a more potent formyl peptide receptor 1 inhibitor than the commonly used peptide antagonists in abolishing neutrophil chemotaxis.
Forsman H; Wu Y; Mårtensson J; Björkman L; Granberg KL; Dahlgren C; Sundqvist M
Biochem Pharmacol; 2023 May; 211():115529. PubMed ID: 37004778
[TBL] [Abstract][Full Text] [Related]
8. The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.
Snapkov I; Öqvist CO; Figenschau Y; Kogner P; Johnsen JI; Sveinbjørnsson B
BMC Cancer; 2016 Jul; 16():490. PubMed ID: 27432059
[TBL] [Abstract][Full Text] [Related]
9. The Expression of Formyl Peptide Receptor 1 is Correlated with Tumor Invasion of Human Colorectal Cancer.
Li SQ; Su N; Gong P; Zhang HB; Liu J; Wang D; Sun YP; Zhang Y; Qian F; Zhao B; Yu Y; Ye RD
Sci Rep; 2017 Jul; 7(1):5918. PubMed ID: 28724995
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus.
Boer JC; Domanska UM; Timmer-Bosscha H; Boer IG; de Haas CJ; Joseph JV; Kruyt FA; de Vries EG; den Dunnen WF; van Strijp JA; Walenkamp AM
Br J Cancer; 2013 Feb; 108(3):587-96. PubMed ID: 23322202
[TBL] [Abstract][Full Text] [Related]
11. Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity.
Minopoli M; Polo A; Ragone C; Ingangi V; Ciliberto G; Pessi A; Sarno S; Budillon A; Costantini S; Carriero MV
Sci Rep; 2019 Aug; 9(1):12169. PubMed ID: 31434916
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.
Schepetkin IA; Khlebnikov AI; Kirpotina LN; Quinn MT
Int Immunopharmacol; 2016 Aug; 37():43-58. PubMed ID: 26382576
[TBL] [Abstract][Full Text] [Related]
13. The formyl peptide fMLF primes platelet activation and augments thrombus formation.
Salamah MF; Ravishankar D; Vaiyapuri R; Moraes LA; Patel K; Perretti M; Gibbins JM; Vaiyapuri S
J Thromb Haemost; 2019 Jul; 17(7):1120-1133. PubMed ID: 31033193
[TBL] [Abstract][Full Text] [Related]
14. Randialic acid B and tomentosolic acid block formyl peptide receptor 1 in human neutrophils and attenuate psoriasis-like inflammation in vivo.
Korinek M; Hsieh PS; Chen YL; Hsieh PW; Chang SH; Wu YH; Hwang TL
Biochem Pharmacol; 2021 Aug; 190():114596. PubMed ID: 33964283
[TBL] [Abstract][Full Text] [Related]
15. V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins.
Zhou C; Zhou Y; Wang J; Feng Y; Wang H; Xue J; Chen Y; Ye RD; Wang MW
Biochem J; 2013 Apr; 451(2):245-55. PubMed ID: 23373827
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.
Minopoli M; Botti G; Gigantino V; Ragone C; Sarno S; Motti ML; Scognamiglio G; Greggi S; Scaffa C; Roca MS; Stoppelli MP; Ciliberto G; Losito NS; Carriero MV
J Exp Clin Cancer Res; 2019 Nov; 38(1):459. PubMed ID: 31703596
[TBL] [Abstract][Full Text] [Related]
18. Identification of C-terminal phosphorylation sites of N-formyl peptide receptor-1 (FPR1) in human blood neutrophils.
Maaty WS; Lord CI; Gripentrog JM; Riesselman M; Keren-Aviram G; Liu T; Dratz EA; Bothner B; Jesaitis AJ
J Biol Chem; 2013 Sep; 288(38):27042-27058. PubMed ID: 23873933
[TBL] [Abstract][Full Text] [Related]
19. The leukocyte chemotactic receptor FPR1 is functionally expressed on human lens epithelial cells.
Schneider EH; Weaver JD; Gaur SS; Tripathi BK; Jesaitis AJ; Zelenka PS; Gao JL; Murphy PM
J Biol Chem; 2012 Nov; 287(48):40779-92. PubMed ID: 23012360
[TBL] [Abstract][Full Text] [Related]
20. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma.
Liu M; Zhao J; Chen K; Bian X; Wang C; Shi Y; Wang JM
Int Immunopharmacol; 2012 Nov; 14(3):283-8. PubMed ID: 22863814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
